We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMEA May Revise Guidelines on Biomarkers for Heart Drugs
EMEA May Revise Guidelines on Biomarkers for Heart Drugs
August 17, 2009
The European Medicines Agency (EMEA) is considering revising its guidelines on the use of surrogate biomarkers for heart drugs — a move that could potentially affect companies producing drugs to treat hypertension or lower lipid levels.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor